Zeiss strenghtens in-house quality and production management

26-Apr-2018 - Germany

ZEISS and GUARDUS have announced that the software solutions supplier for computer-supported quality assurance and production management systems based in the German city of Ulm has become a wholly owned subsidiary of the ZEISS Group.

Carl Zeiss AG

Simone Cronjäger, Founder and Managing Director of GUARDUS, and Dr. Jochen Peter, Member of the Executive Board of the ZEISS Group and President & CEO of Carl Zeiss Industrielle Messtechnik GmbH, announcing ZEISS' acquisition of GUARDUS

Carl Zeiss AG

The software solutions from GUARDUS provide decision intelligence for managing Smart Factories.

Carl Zeiss AG
Carl Zeiss AG

For ZEISS, the integration of GUARDUS into its Industrial Metrology (IMT) business group will further strengthen its own position as a partner for increasing productivity in digital manufacturing. The Computer Aided Quality (CAQ) applications and Manufacturing Execution Systems (MES) from GUARDUS provide customers with a fully integrated analysis and steering function for production.

"With GUARDUS, we will enhance our software solutions like ZEISS PiWeb with a comprehensive database not previously available, enabling us to offer our customers even more holistic services. Together we are striving for a new level of integrated solutions for agile process management. We want to supply the foundation for automated control processes, learning systems and simulation methods for networked and intelligent quality assurance in the Smart Factory," says Dr. Jochen Peter, Member of the Executive Board of the ZEISS Group and President & CEO of Carl Zeiss Industrielle Messtechnik GmbH.

"We are convinced that, by being directly integrated in the ZEISS Group with its large installed base, GUARDUS will enjoy even better conditions for driving further developments and continued strong growth," says Simone Cronjäger, Company Founder and Managing Director of GUARDUS. She adds, "Integrating solutions from GUARDUS and thus all vertical and horizontal information processes will enable unprecedented decision intelligence – extending from the field and control levels all the way to the comprehensive process and plant management levels."

Initially, the joint customer focus will be on the automotive and engineering industries as well as medical technology. GUARDUS' existing sites in Ulm and Timisoara, Romania will be retained. For the approximately 60 employees, business operations will be transferred as per German legal provisions.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Creabilis Raises €15M in Series B Fundraising Round

Biocitech life science park boosts scientific score in 2008 - Biocitech residents further improve performance with 34 patents applied for, six new proofs of concept, seven pre-clinical trials and two clinical trials under way, 18 major scientific advances and a wide range of publications and scientific presentations

Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

Intercell announces start of pivotal Phase II/III study in India for vaccine to protect children from Japanese Encephalitis

Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD

Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer

Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer

Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus

Novel gene drives development of different types of ovarian cancer

Discovery of 100 million-year-old regions of DNA shows short cut to crop science advances